
    
      Phase 3 clinical study of FS-1 drug is a randomized, interventional, multicenter,
      placebo-controlled (add-on), double-blind and two arms trial.

      The study consists of two following phases: treatment phase - 6 months and follow-up phase 12
      months. It is planned to recruit 480 patients with verified MDR-TB diagnosis.

      All data will be compiled in an Electronic Data Capture System with further statistical
      analysis according to approved Statistical Analytical Plan.
    
  